1 option
Ferumoxytol versus other intravenous iron therapies for anemia : a review of the clinical and cost-effectiveness and guidelines - an update.
- Format:
- Book
- Series:
- Rapid response report (Canadian Agency for Drugs and Technologies in Health).
- NCBI Bookshelf.
- Rapid response report: summary with critical appraisal 1922-8147
- NCBI Bookshelf
- Language:
- English
- Subjects (All):
- Iron compounds--Therapeutic use.
- Iron compounds.
- Iron deficiency anemia--Chemotherapy.
- Iron deficiency anemia.
- Ferrosoferric Oxide--therapeutic use.
- Anemia, Iron-Deficiency--drug therapy.
- Cost-Benefit Analysis.
- Medical Subjects:
- Ferrosoferric Oxide--therapeutic use.
- Anemia, Iron-Deficiency--drug therapy.
- Cost-Benefit Analysis.
- Physical Description:
- 1 online resource (1 PDF file (21 pages)) : illustrations.
- Place of Publication:
- [Ottawa] : Canadian Agency for Drugs and Technologies in Health, 21 November 2014.
- Summary:
- Ferumoxytol (Feraheme) is a colloidal superparamegnetic iron-carbohydrate complex that was specifically designed to reduce immunological reactivity. It can be rapidly administered (IV rate of 30-60 seconds) as a 510 mg dose with the second IV injection administered two to eight days later. The federal Food and Drug Administration (FDA) in the United States has listed ferumoxytol for the treatment of iron deficiency anemia (IDA, characterized by iron deficiency) in adult patients with chronic kidney disease (CKD). Health Canada has recently placed restrictions on the use of ferumoxytol due to the potential for serious allergic reactions. Therefore, this review was performed to assess the clinical effectiveness and safety of ferumoxytol compared with other IV iron therapies for patients with IDA. In addition, cost-effectiveness and evidence-based guidelines were also investigated to determine the costs associated with ferumoxytol and its use in patients with IDA. This is an update to a previous review on ferumoxytol which found limited evidence that stated that it seemed to have comparable efficacy to other iron complexes but that it was associated with an increased adverse event profile.
- Notes:
- Description based on version viewed March 20, 2015.
- Includes bibliographical references.
- OCLC:
- 905229940
- Publisher Number:
- 245171 CaOOCEL (Public Documents)
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.